μCaler FS EMS+ Panel v1.0

Feature

• Sample Compatibility: Suitable for gDNA, cfDNA, and various levels of FFPE samples
• Pan-cancer Detection:Simultaneously covers large-scale CpG sites of multiple genes for 10 major high-incidence cancers worldwide.
• Flexible Customization:Supports tailored probe sets with various CpG site scales and/or gene mutations for single or multiple cancer types, enabling simultaneous detection of methylation and mutations.
• Accurate Quantification:Achieves precise quantification of methylation levels (0~100%) in tested samples.
• Efficient Capture:Combined with μCaler DNA Full Screen System, requires no sequence conversion and retains native sequence complexity, significantly enhancing effective coverage depth.
• Ultra-high Sensitivity:Compatible with dual-end unique molecular identifier (UMI) adapters for ultra-sensitive detection of low to ultra-low abundance signals.
  

Performance

Accurate Quantification of Methylation Levels

Figure 1. Accurate quantification of simulated samples with different methylation levels by μCaler FS EMS+ Panel v1.0. A. Comparison between theoretical and observed methylation levels; B. Methylation levels of CpG sites in target regions. Simulated samples were hybrid captured using the μCaler DNA Full Screen System and μCaler FS EMS+ Panel v1.0. Sequencing was performed on DNBSEQ-T7 (PE150) and NovaSeq 6000 (PE150). For each sample, 1.0 M reads pair of data was randomly selected for data analysis.
Note: The samples were simulated DNA prepared by using human 100% Methylated DNA standard (Zymo, D5014-2) positive control and 0% Methylated DNA standard (Zymo, D5014-1) negative control to mimic different methylation levels (0%, 10%, 50% and 100%). The initial input amounts for both simulated samples with different methylation levels were 50ng.

Maintaining High Stability of Methylation Detection

Figure 2. Consistency between two methylation level measurements of one sample by μCaler FS EMS+ Panel v1.0. A-D. Methylation level correlation between two replicates of 4 independent samples. 4 clinical tumor samples were randomly selected (A & B: colorectal cancer, C & D: bladder cancer) and hybrid capture was performed using the μCaler DNA Full Screen System and μCaler FS EMS+ Panel v1.0. The R² values for correlation ranged from 0.9279 to 0.9707.
Note: Initial sample input was 20 ng.

Effectively Distinguishing Tumor and Peritumoral Tissues

Figure 3. Methylation level detection of μCaler FS EMS+ Panel v1.0 applied to clinical colorectal cancer and peritumoral tissue samples. A. CpG methylation levels in paired colorectal cancer samples; B. CpG methylation levels of colorectal cancer candidate biomarkers in clinical samples.
Note: CRCA: Colorectal Cancer; Pt: Peritumoral tissue. Control refers to Human Genomic DNA standard (Promega, G1471), with an input of 20 ng.

Genelist

Type of cancer	Biomarkers
Lung cancer	BCAT1	CDH1	CDKN2A	CDO1	DMRTA2	FOXD3	FOXI2	GATA5	GDNF	HOXA7
	HOXA9	OPCML	PAX5	PTGER4	RASSF1	SCT	SHOX2	SIX6	SLC12A8	SOX17
	ST6GALNAC5	SULF2	TAC1	TNFRSF25	ZFP42
Breast cancer	APC	ASCL1	BRCA1	C1QL3	CPXM1	DKK3	GALR1	HOXA10	HOXA9	ITIH5
	LBX1	OTP	PITX2	RARB	RASGRF1	SOX1	USP44
Colotectal cancer*	ADHFE1	ALX4	ASCL1	BCAT1	BMP3	C1QL3	CNRIP1	EYA4	FBN1	FGF5
	IKZF1	INA	MAL	NDRG4	NPY	OPCML	RARB	SDC2	SEPTIN9	SFRP2
	SIX6	SNCA	SOX1	SPART	ST6GALNAC5	TAC1	TFPI2	TM6SF1	VAV3
Prostate cancer	AKR1B1	ANXA2	AOX1	APC	CFAP90	GDAP1L1	GSTP1	HAAO	PRKCB	PTGS2
	RARB	RUNX3	SEPTIN9	SIX6	TAC1
Gastric cancer	ADRA1B	ARHGAP20	ASCL1	C1QL3	CABIN1	CD40	CPEB1	DLGAP3	DOCK10	ELMO1
	HOPX	HOXD11	KCNQ5	LMX1A	RNF180	RORB	RPRM	RUBCNL	RUNX3	SDC2
	SEPTIN9	TCF4	TFPI2	ZNF569
Liver cancer	ALX3	ARHGEF33	C1QL3	CDKL2	CFTR	DCDC2	EVX1	FAR1	HOXA11	HOXA9
	MTHFD2	PLAC8	RIPK3	RUNX3	SEPTIN9	SGIP1	SH3YL1	SIX6	SOX1	TAMALIN
	TBX15	WNT3A	ZNF605
Cervical cancer	ASCL1	ASTN1	C1QL3	CHAD	CHRM2	DLX1	EDN3	EPB41L3	FGF10	HOXA9
	ITGA4	ITGA8	JAM3	OPCML	PAX1	PCDHGB7	RXFP3	SEPTIN9	SIX6	SOX1
	SOX17	ST6GALNAC5	TAC1	TAFA4	TFPI2	ZNF582	ZNF781	ZSCAN1
Bladder cancer	EOMES	FEZF2	HAND2	IRAK3	IRX4	LRRC4	NID2	NOVA1	NRN1	ONECUT2
	OTX1	PENK	PIGG	SOX1	TAC1	TCERG1L	TMEFF2	TWIST1	VIM
Esophaheal cancer	ASCL1	CCNA1	EPO	HOXC10	HOXD1	KCNA3	MAFB	MT1A	MT1G	OPCML
	RAB37	RAPGEFL1	SEPTIN9	SIX6	ST3GAL6	ST6GALNAC5	TAMALIN	TFPI2	ZNF132	ZNF154
	ZNF582
Ovarian cancer	CDH13	CDO1	GYPC	HNF1B	HOXA11	HOXA9	IFFO1	LOC284798	LYPD5	OPCML
	PAX1	PCDH17	PCDHB18P	RASSF1	RYBP	SOX1	TAC1	ZNF671

*It also covers intergenic regions not listed in the table (Intergenic, containing 12 CpG sites).

For research use only. Not for use in diagnostic procedures.